arrow
V

Vittorio Ruggero Zilioli

Università di Modena e Reggio Emilia
H指数:20
被引数:1,349

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Role of direct-acting antivirals in people with HIV-associated non-Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi

直接抗病毒药物在合并HCV感染的HIV相关非霍奇金淋巴瘤患者中的作用:意大利淋巴瘤基金会研究

2026-09-060
PRE
RENOIR phase 3 rituximab-lenalidomide vs rituximab as maintenance treatment in relapsed/refractory follicular lymphoma

RENOIR三期研究:利妥昔单抗-来那度胺对比利妥昔单抗作为复发/难治性滤泡性淋巴瘤的维持治疗

2026-09-010
PRE
Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial

自体移植后复发/难治性滤泡性淋巴瘤患者继发恶性肿瘤风险增加:FIL-FLAZ12 III期试验的长期结果

2026-08-120
OAAI
Clonal hematopoiesis dynamics influences long-term outcomes of follicular lymphoma: Results from FIL FOLL12 trial

克隆性造血动态影响滤泡性淋巴瘤的长期结局:FIL FOLL12试验结果

2026-05-200
OAAI
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial

通过分析微小残留病动态改善套细胞淋巴瘤的预后预测:意大利淋巴瘤基金会(FIL)MCL0208临床试验数据

2026-04-300
OAAI
Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL)

次级遗传事件及其与Mantle Cell Lymphoma中TP53突变的关系:一项来自FIL_MANTLE-FIRST BIO的亚组研究,代表意大利淋巴瘤基金会(FIL)

Cancers
IF4.4
2026-03-040
OAAI
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE-FIRST study

老年套细胞淋巴瘤患者中,首次进展时间和体能状态的作用:ELDERLY MANTLE-FIRST研究的结果

2025-12-010
OAAI
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

IELSG37试验中免疫化疗方案对原发性纵隔B细胞淋巴瘤患者预后的影响

Blood
IF23.1
2025-09-150
PRE
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a Fondazione Italiana Linfomi Cohort Study

R-miniCOMP与R-miniCHOP在老年非适合型弥漫大B细胞淋巴瘤患者中的比较疗效:来自意大利淋巴瘤基金会队列研究的见解

2025-05-130
PRE
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients

FIL MCL0208试验中,来那度胺维持治疗与观察在MCL患者自体干细胞移植(ASCT)后的长期结果

2025-03-220
OAAI
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study
2024-12-100
OAAI
Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL)

V-Rbac背景下微小残留病评估,一项Fondazione Italiana Linfomi (FIL)风险定制II期临床试验

BLOOD
IF23.1
2024-11-050
PRE
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial

放射免疫疗法与自体造血干细胞移植治疗复发/难治性滤泡性淋巴瘤: 一项多中心,随机,III期临床试验

2024-01-010
OA
Parsaclisib, a PI3Kd inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study

Parsaclisib,一种PI3Kd抑制剂,用于复发和难治性套细胞淋巴瘤 (CITADEL-205): 一项2期研究

2023-08-014
OAAI
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma
2023-08-015
OAAI
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
2023-07-278
OAAI
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study
LEUKEMIA
IF13.4
2023-01-1818
OAAI
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)
2022-11-1713
OAAI
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi
2022-10-077
PRE